Among numerous sessions to be held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

FFPE-Based Molecular Classifier Precisely Separates Eczema From Psoriasis

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Determining Systemic Therapy Eligibility in Patients With Atopic Dermatitis

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

Using Biologic Treatments in Atopic Dermatitis

Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."

Systemic Treatment, Immunosuppressants, and JAK Inhibitor Session Highlights

Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.

Christopher Bunick, MD, PhD, Discusses Late-Breaking Long-Term 4-Year Safety Data of Upadacitinib for AD

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

Revolutionizing Atopic Dermatitis Recap: Day 2

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.

The Science of Atopic Dermatitis With Anna De Benedetto, MD

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

No Differences in Severity or Treatment Among Racially Diverse Eczema Patients

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

Boxed Warnings Should Not Create a Fear of Using All JAK Inhibitors for AD

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

Lebrikizumab Efficacious in Clearing Hand, Facial Atopic Dermatitis

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Upadacitinib, Long-Term Control, and Tapinarof, Oh My!

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

Crisaborole Ointment Leads to Significant, Consistent Improvements in AD

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

New Drugs in 2023, Patient Satisfaction, and RAD Takeaways With Melinda Gooderham, MSc, MD, FRCPC

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

Late-Breaking Data: Dupilumab Significantly Improves Signs, Symptoms, and QoL in Patients With Hand & Foot Dermatitis

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Abrocitinib Has Acceptable Long-Term Safety Profile in Adolescents with AD

Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.

Revolutionizing Atopic Dermatitis Recap: Day 3

Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.

Crucial Conversations Are Needed to Address Racism in Medicine

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.

Dupilumab Efficacious in Pediatric Patients as Young as 6 Months

The drug was both safe and effective in patients ages 6 months to 5 years.

Digital Educational Intervention Increases Awareness Among Hispanic Patients With AD

The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.

Assessing Itch Severity and Skin Clearance Supports Shared Decision Making

New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.